Shares of SCYNEXIS Inc (NASDAQ:SCYX) have earned an average rating of “Buy” from the ten analysts that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $5.29.
A number of brokerages have issued reports on SCYX. Maxim Group lowered their target price on SCYNEXIS from $6.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, October 16th. Zacks Investment Research cut SCYNEXIS from a “buy” rating to a “hold” rating in a report on Friday. ValuEngine raised SCYNEXIS from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. HC Wainwright set a $5.00 price target on SCYNEXIS and gave the company a “buy” rating in a research note on Tuesday, October 23rd. Finally, Brookline Capital Management reissued a “buy” rating on shares of SCYNEXIS in a research note on Friday, January 4th.
SCYX traded up $0.18 on Monday, reaching $1.34. The stock had a trading volume of 3,152,070 shares, compared to its average volume of 1,961,073. SCYNEXIS has a fifty-two week low of $0.35 and a fifty-two week high of $2.15. The company has a quick ratio of 4.53, a current ratio of 4.53 and a debt-to-equity ratio of 0.27. The stock has a market cap of $57.28 million, a PE ratio of -1.33 and a beta of 2.28.
SCYNEXIS (NASDAQ:SCYX) last issued its earnings results on Tuesday, November 13th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.18. SCYNEXIS had a negative return on equity of 102.52% and a negative net margin of 8,592.97%. The business had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.06 million. On average, equities research analysts expect that SCYNEXIS will post -0.51 EPS for the current year.
Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new stake in shares of SCYNEXIS in the second quarter valued at about $190,000. Northern Trust Corp increased its stake in shares of SCYNEXIS by 132.7% in the second quarter. Northern Trust Corp now owns 116,079 shares of the company’s stock valued at $190,000 after buying an additional 66,193 shares during the period. BlackRock Inc. increased its stake in shares of SCYNEXIS by 61.5% in the second quarter. BlackRock Inc. now owns 180,751 shares of the company’s stock valued at $296,000 after buying an additional 68,830 shares during the period. Private Advisor Group LLC acquired a new stake in shares of SCYNEXIS in the third quarter valued at about $240,000. Finally, Stonepine Capital Management LLC acquired a new stake in shares of SCYNEXIS in the third quarter valued at about $539,000. 41.53% of the stock is owned by institutional investors.
SCYNEXIS Company Profile
SCYNEXIS, Inc, a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.
Featured Story: Understanding Specialty Certificates of Deposit
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.